Prevalence and Predictors of Low Serum 25-Hydroxyvitamin D among Female African-American Breast Cancer Survivors by Sheean, Patricia M et al.
Loyola University Chicago 
Loyola eCommons 
School of Nursing: Faculty Publications and 
Other Works Faculty Publications 
4-2018 
Prevalence and Predictors of Low Serum 25-Hydroxyvitamin D 
among Female African-American Breast Cancer Survivors 
Patricia M. Sheean 
Loyola University Chicago, psheean1@luc.edu 
Claudia Arroyo 
Jennifer Woo 
Melinda Stolley 
Follow this and additional works at: https://ecommons.luc.edu/nursing_facpubs 
 Part of the Nursing Commons, and the Oncology Commons 
Recommended Citation 
Sheean, Patricia M.; Arroyo, Claudia; Woo, Jennifer; and Stolley, Melinda. Prevalence and Predictors of 
Low Serum 25-Hydroxyvitamin D among Female African-American Breast Cancer Survivors. Journal of 
the Academy of Nutrition and Dietetics, 118, 4: 568-577, 2018. Retrieved from Loyola eCommons, School 
of Nursing: Faculty Publications and Other Works, http://dx.doi.org/10.1016/j.jand.2017.10.009 
This Article is brought to you for free and open access by the Faculty Publications at Loyola eCommons. It has 
been accepted for inclusion in School of Nursing: Faculty Publications and Other Works by an authorized 
administrator of Loyola eCommons. For more information, please contact ecommons@luc.edu. 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License. 
© Academy of Nutrition and Dietetics 2018 
1 
 
Title: Prevalence and predictors of low serum 25(OH)D among female African-1 
American breast cancer survivors 2 
 3 
Research Snapshot: 4 
Research Questions: 5 
What is the prevalence of low serum 25(OH)D among female African American (AA) 6 
breast cancer (BC) survivors? What modifiable factors are significant predictors of 7 
serum 25(OH)D levels in these minority women? 8 
 9 
Key Findings: 10 
In this cross-sectional study comprised of 244 early stage AA BC survivors with 11 
overweight/obesity, vitamin D deficiency was prevalent in 81% and 43% of women, 12 
applying the cut-points of the Endocrine Society (<30 ng/ml or <75 nmol/L) and the 13 
Institute of Medicine (<20 ng/ml or <50 nmol/L), respectively. Interestingly, 60% of 14 
participants endorsed habitual use of vitamin D supplementation. In multivariate 15 
modeling, Vitamin D supplementation, sun behaviors and waist hip ratio were significant 16 
predictors of serum 25(OH)D levels and thus, may serve as future points of intervention 17 
to improve the vitamin D status of this minority survivor population. 18 
  19 
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Abstract 20 
Background: African-American (AA) breast cancer (BC) survivors commonly 21 
demonstrate low serum 25(OH)D. Decreased cutaneous conversion, high levels of 22 
adiposity and even BC treatment may influence vitamin D status. Previous 23 
investigations have analyzed AA women in aggregate with other BC survivors and have 24 
not comprehensively addressed these influential factors. 25 
Objective: To determine the prevalence of low serum 25(OH)D in an exclusively AA 26 
cohort of female BC survivors with overweight/obesity. And further, to evaluate the role 27 
of ultraviolet (UV) light exposure, body composition, and dietary sources of vitamin D on 28 
serum 25(OH)D levels. 29 
Design: Cross-sectional 30 
Participants: Pre- and post-menopausal AA BC survivors (n=244) were recruited from 31 
various neighborhoods in the city of Chicago between September, 2011 – September, 32 
2014 for a larger weight loss trial.  33 
Main outcome measures: Demographic, clinical, anthropometric [body mass index 34 
(BMI), waist (WC) and hip circumference (HC)], blood biospecimen, dietary intake [Food 35 
frequency questionnaire (FFQ)] and sun behavior data were collected by trained study 36 
personnel prior to trial participation. Dual energy x-ray absorptiometry (DXA) was used 37 
to quantify adiposity (total, %, regional, visceral) and lean mass. Serum 25(OH)D was 38 
used as the biomarker reflective of vitamin D status. 39 
Statistical analyses: Mean (± standard deviation), frequencies and multivariate linear 40 
regression modeling  41 
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Results: The average participant was 57.4 (± 10.0) y, 6.9 (± 5.2) y from initial BC 42 
diagnosis with a BMI of 36.2 (± 6.2) kg/m2. The majority of participants (60%) reported 43 
habitual oral vitamin D supplementation with mean intakes of 327 (± 169) IUs.  Vitamin 44 
D deficiency was prevalent in 81% and 43%, applying the cut-points of the Endocrine 45 
Society (<30 ng/ml or <75 nmol/L) and the Institute of Medicine (<20 ng/ml or <50 46 
nmol/L), respectively. A multivariate model adjusting for age, seasonality of blood draw, 47 
total energy intake, supplemental vitamin D, darker skin pigmentation, BC stage and 48 
waist hip ratio (WHR) was able to explain 28.8% of the observed variance in serum 49 
25(OH)D concentrations. No significant associations were detected for BMI or any DXA 50 
measures of body composition. 51 
Conclusions:  52 
Considering the number of women endorsing the use of vitamin D supplementation, the 53 
prevalence of vitamin D deficiency among these AA BC survivors was high. Vitamin D 54 
supplementation, sun behaviors and WHR may serve as future points of intervention to 55 
improve the vitamin D status of this minority survivor population.   56 
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INTRODUCTION 57 
Vitamin D is a generic term designating a group of chemically related compounds 58 
best known for their antirachtic activity. Serum 25(OH)D is the generally accepted 59 
biomarker for determining vitamin D status.1  It is well known that serum 25(OH)D is 60 
derived from sun exposure and that dietary sources of vitamin D (e.g., egg yolks, 61 
salmon, tuna, and fortified dairy products) contribute less significantly to these levels.2 62 
Because vitamin D influences the expression of genes that are associated with the 63 
development and progression of breast cancer (BC),3,4 intensive efforts over the last 64 
two decades have sought to elucidate the role of 25(OH)D, BC occurrence and BC 65 
outcomes.  66 
While the exact mechanisms remain unknown, BC treatment, itself, appears to 67 
be associated with lower levels of serum 25(OH)D. Approximately 70-75% of female BC 68 
survivors are classified as vitamin D deficient/insufficient,5-7 which is higher than 69 
population estimates.8 These previous BC studies, while informative, are limited by two 70 
notable factors. First, the majority of BC survivors enrolled were non-Hispanic white with 71 
relatively small numbers of African American (AA) BC participants by comparison. 72 
Decreased cutaneous conversion of 7-dehydrocholesterol to cholecalciferol occurs with 73 
higher melanin content.9  Accounting for skin pigmentation and sun behaviors are 74 
informative, yet understudied areas in the context of serum 25(OH)D and BC. Second, 75 
body mass index (BMI) has been used a surrogate marker of adiposity.10,11 This 76 
approach is an attempt to address the inverse relationship between obesity and 77 
25(OH)D.11 However, a systematic review and meta-analyses of 31,968 participants 78 
reveals that BMI fails to detect half of the people with excess adiposity;12 thus its 79 
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application as a surrogate marker for adiposity is questionable. Therefore, the objective 80 
of this investigation is to examine serum 25(OH)D levels in an exclusively AA cohort of 81 
female BC survivors with overweight/obesity. The present study is novel, in that, it 82 
simultaneously addresses important non-modifiable (i.e., BC treatment, sex, 83 
race/ethnicity) and modifiable factors (e.g., sun exposure, adiposity) using 84 
methodologies that can accurately measure body composition and tools that can 85 
capture important contributors to serum 25(OH)D, such as skin color or sun behaviors. 86 
This study addresses notable shortcomings of previous work in an effort to more 87 
precisely establish the prevalence and predictors of low serum 25(OH)D and to identify 88 
potential intervention points among these minority BC survivors. We hypothesize that 89 
the majority of the participants will be classified as vitamin D deficient, and that darker 90 
skin pigmentation and higher levels of percent body fat will negatively predict serum 91 
levels of 25(OH)D. 92 
METHODS 93 
Study participants  94 
Study participants reflect AA BC survivors recruited from various communities 95 
within Chicago, Illinois between September, 2011 – September, 2014 for a larger 96 
randomized behavioral weight loss trial.  These present analyses use a cross-sectional 97 
study design of data collected at baseline for prevalence estimates. The specific study 98 
methodologies have been described previously.13 Briefly, eligible adult women: 1) self-99 
identified as Black or AA females; 2) self-reported Stage I-III invasive breast carcinoma; 100 
3) were overweight (BMI 25.0-29.9 kg/m2) or obese (BMI >30.0 kg/m2), and 4) 101 
completed surgery, chemotherapy and/or radiation treatment at least six months prior to 102 
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recruitment. Current use of adjuvant hormonal therapies was acceptable.  Women were 103 
excluded for the following: 1) plans to relocate out of the Chicago area during the time 104 
of study participation, 2) unable to safely engage in physical activity due to physical 105 
impairments requiring a wheelchair or walker, a diagnosis of emphysema or extreme 106 
dyspnea on exertion, 3)  currently pregnant, planning to get pregnant or less than 3 107 
months post-partum, 4) formally enrolled in a weight loss program requiring specialty 108 
foods  or meal replacements, 5) taking prescription weight loss agents; or 6) 109 
experiencing any psychiatric conditions that precluded study participation. The study 110 
received ethical approval from the Institutional Review Boards of the University of 111 
Illinois, University of Chicago and Northwestern University.  112 
Procedures 113 
Women were screened for initial eligibility over the telephone by the study 114 
recruiters. (Figure 1) A baseline interview was scheduled for eligible women, written 115 
informed consent was obtained and variety of questionnaires were completed. Within 116 
one month of the baseline interview, eligible/interested women returned for blood draw, 117 
anthropometric measures and DXA completion.  118 
Data collection 119 
Demographic and clinical data, including co-morbid conditions, menopausal 120 
status, BC stage, date of diagnosis, BC treatments [e.g., chemotherapy (yes/no), 121 
radiation (yes/no), current or previous endocrine therapies [selective estrogen receptor 122 
modulators or aromatase inhibitors] and other medications were self-reported. 123 
Oncologists were contacted to verify disease stage, when needed. Women with Stage 0 124 
or IV were precluded further participation.  125 
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 Phlebotomy and body composition assessment were completed on the same day 126 
prior to participation in the weight loss trial. Blood draws were completed by trained 127 
phlebotomists, transported and processed by a certified clinical laboratory on the same 128 
day. The best marker for vitamin D status is serum 25(OH)D, which is comprised of 129 
25(OH)D3 and 25(OH)D2.1,14 Serum 25(OH)D levels were quantified using the DiaSorin 130 
Liaison 25 OH vitamin D total assay, which uses chemiluminescent immunoassay 131 
technology for the quantitative determination of 25(OH)D  and other hydroxylated 132 
vitamin D metabolites.  133 
Height was measured to the nearest 0.1 cm using a portable stadiometer (Seca 134 
213; Chino, CA) and weight was measured to the nearest 0.1 kg using a digital scale 135 
(Tanita BWB 800S; Arlington Heights, IL). Participants wore light clothes and were 136 
measured without shoes. Measurements were obtained by trained study personnel. If 137 
two measurements were more than 0.5 cm or 0.2 kg apart for height and weight, 138 
respectively, a third measurement was taken. The two closest measures of height and 139 
weight were used to calculate and classify BMI (kg/m2).15 140 
Waist and hip measures, surrogate measures of visceral and gluteal adiposity, 141 
respectively, were completed by trained study staff based on the National Health and 142 
Nutrition Examination Survey techniques.16 However, the umbilicus was used as the 143 
external marker for waist circumference (WC). Waist and hip circumference were 144 
measured by placing a Gulick II Plus measuring tape in the horizontal plane (parallel to 145 
the floor) around the abdomen at the umbilicus for WC or at the widest point over the 146 
buttocks for hip circumference (HC). Participants were told to wear light clothing to allow 147 
direct measurement on the skin, assuring the removal or minimum inclusion of bulky 148 
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clothing (e.g., seams, gathered material from pants, shirts or other garments) in the 149 
measurement. Participants were further instructed to breathe normally and stand with 150 
ankles as close together as possible. A second staff member ensured that the 151 
measuring tape was parallel to the floor with measurements taken in duplicate to the 152 
nearest 0.1 cm and recorded. Additional measurements were taken and recorded until 153 
two measurements were within 1.0 cm of each other.  154 
Body composition was measured using DXA (iLunar, GE, software version 13.6). 155 
(Figure 2) Following daily calibration with the manufacturer’s phantom, whole body 156 
scans were performed and analyzed by a trained technician blind to study group or 157 
outcomes. For measuring android fat, a region of interest was automatically deﬁned 158 
using the methods of Kaul et al.17 Abdominal and visceral were obtained from the 159 
android region. Random whole body and hip images were periodically reviewed by a 160 
certified bone densitometrist for quality assurance purposes. Errors were corrected, 161 
techniques were altered to prevent future errors, and images were reanalyzed as 162 
needed prior to download and statistical analyses.  163 
 The Block 2005 Food Frequency Questionnaire (FFQ), a validated,18 110-item 164 
dietary assessment tool, was administered in person by trained personnel and 165 
processed by NutritionQuest (Berkeley, CA) to procure habitual dietary intakes reflective 166 
of the previous 6 months for vitamin D from food, beverage and dietary supplements 167 
sources. To account for important, non-dietary sources of vitamin D, we quantified 168 
summer sunlight exposure (focusing on weekend and weekday ‘hours outside’), 169 
addressed seasonal influence of blood draw (i.e., participants drawn June- September 170 
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vs. October-May) and we categorized participants into one of six levels of self-reported 171 
skin pigmentation.19 172 
STATISTICAL ANALYSES 173 
Because of the current lack of agreement on levels used to classify deficiency, serum 174 
25(OH)D cut-points proposed by, both, the Endocrine Society20 and the Institute of 175 
Medicine (IOM),21 were applied. Means, medians, standard deviations, and ranges were 176 
used to describe the distribution of the data. Non-normally distributed variables were log 177 
transformed for analyses. Student’s t and Wilcoxon rank-sum tests for continuous 178 
variables and Chi square for categorical variables were conducted for comparisons 179 
between deficient and non-deficient participants. Multivariate linear regression analyses 180 
were conducted to determine the characteristics that independently predicted serum 181 
25(OH)D, after adjustment for other variables. Informed by our preliminary analyses and 182 
previous studies, several covariates were included in the models due to their abilities to 183 
predict serum 25(OH)D (e.g., age, seasonality of blood draw, diet/supplement 184 
contribution.)  Reasoning that dark skin would impede ultraviolet light the most, self-185 
reported untanned skin was reduced to a two categories [“dark” (i.e., dark brown and 186 
very dark) vs. “light” (very fair, fair, olive and light brown)]. Variables were only retained 187 
in the multivariate models if the effect of the variable changed the point estimate by 188 
>10% or if the variable was significant in the multivariate model (p ≤ 0.05). Collinearity 189 
was assessed prior to the final modeling and only one variable was selected for model 190 
fitting (e.g., dietary vitamin D vs. total energy intake, visceral adipose tissue (VAT) mass 191 
vs. android fat mass). Statistical analysis was conducted using the statistical program 192 
SAS (version 9.4).22 193 
10 
 
RESULTS 194 
The average age of the participants (N=244) was 57.4 y (±10.0) and 11% (n=27) had 195 
overweight (BMI 25.0-29.9), 23% (n=99) had Class 1 obese (BMI 30.0-34.9), 26% 196 
(n=63) had Class 2 obese (35.0-39.9) and 40% (n=55) had Class 3 obese (BMI ≥ 40.0). 197 
Participants were predominantly non-smokers (91%, n= 219), diversely educated [39% 198 
(n= 95) completed some college and 38% (n= 93) possessed a college and/or graduate 199 
degree] and 50% (n=122) were privately insured. The average body weight, BMI and 200 
WHR was 96.1 (±18.2) kg, 36.2 (±6.2) kg/m2 and 0.94 (±0.09), respectively. Self-reports 201 
of diabetes, high blood pressure and high serum cholesterol were 53%, 59% and 38%, 202 
respectively, signifying an overall high prevalence of co-morbid conditions. The average 203 
time since BC diagnosis was 6.9 (±5.2) y, with 73% (n=175) and 79% (n=189) of 204 
women self-reporting previous chemotherapy or radiation treatment, respectively.  205 
The demographic and clinical characteristics of the study participants stratified by 206 
vitamin D cut-points are presented in Table 1. The mean serum 25(OH)D was 22.5 207 
(±10.8) mg/dL [56.2 (±27.0)]. The prevalence of vitamin D deficiency was 81% and 43% 208 
using the values of the Endocrine Society and IOM, respectively. Individuals classified 209 
as vitamin D sufficient by Endocrine society tended to be older at the time of study 210 
enrollment (p=0.003) and at BC diagnosis (p=0.02), reported a lower occurrence of 211 
diabetes (p=0.017) and hypertension (p=0.002) and were more often employed fulltime 212 
or retired when compared to individuals classified as insufficient. Individuals classified 213 
as vitamin D sufficient using the IOM cut-points were older at the time of BC diagnosis 214 
(p=0.037) and more likely to report early disease stage (p=0.001) and hypertension 215 
(p=0.025).  216 
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Table 2 depicts the bivariate analyses of potential predictors of serum 25(OH)D 217 
using dichotomized definitions of vitamin D status. Due to changes from a shorter to a 218 
longer version of the FFQ, only dietary data from recruitment sites 2-8 were evaluable 219 
(n=219). When stratified by the Endocrine Society cut-points, participants who were 220 
classified as insufficient reported darker skin pigmentation (p= 0.01). When stratified by 221 
the IOM cut-points, participants who were classified as insufficient had higher android 222 
fat mass measurements (p<0.001), higher energy (p<0.001) and dietary vitamin D 223 
intake (p<0.001). In addition, mean serum 25(OH)D levels were significantly higher for 224 
participants who had blood draws in June-September vs. October-May (24.6 ± 10.8 vs. 225 
21.2 ± 10.7, respectively; p=0.02). 226 
Linear regression modeling involved examining the associations between lifestyle, 227 
clinical and BC treatment related variables with log transformed serum 25(OH)D. 228 
Significant independent associations between serum 25(OH)D and age (β= 0.00868; 229 
p=0.008), dietary vitamin D, IU (β= -0.001; p= 0.05), vitamin D supplementation, IU (β= 230 
0.00111; p<0.001), total energy intake, kcals (β= -0.00013; p<0.001) and seasonality of 231 
blood draw (β= 0.20384; p=0.002) were detected. None of the variables related to BC 232 
disease status or treatment (alone or in combination) were independently associated 233 
with serum 25(OH)D (p >0.05). Initially, the following body composition variables were 234 
inversely associated with serum 25(OH)D: weight (p= 0.02), waist (p=0.03), total fat 235 
mass (p=0.02), VAT mass (p=0.04), android fat mass (p=0.01), gynoid fat mass 236 
(p=0.04), total lean mass (p=0.02) and ALH (p=0.04).  Linear regression modeling 237 
involved assessing the effects of the various body composition variables on log 238 
transformed serum 25(OH)D. Our final multivariate model was able to explain 28.8% of 239 
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the observed variance in serum 25(OH)D concentrations, adjusting for age (β= 240 
0.00049), seasonality of blood draw (β= 0.15096), total energy intake, kcals (β= -241 
0.00011), supplemental vitamin D (β= 0.00107), darker skin pigmentation (β= -0.08668), 242 
and BC stage (β= -11236)  and WHR (β= -0.79472). No significant associations were 243 
detected for BMI or any DXA measures of body composition. 244 
DISCUSSION 245 
The interpretation of our study findings is not straightforward owing to the 246 
variation in how vitamin D deficiency is defined. When we apply the more conservative 247 
IOM cut-point of <20 ng/ml (<50 nmol/L), we found that 43% of our AA female BC 248 
survivors were classified as vitamin D deficient. Considering that 82% of AAs (≥ 20 249 
years of age) participating in the NHANES are classified as vitamin D deficient,23 we 250 
view our results as discrepant, yet positive. However, when we apply the more liberal 251 
cut-point of the Endocrine Society (<30 ng/ml or <75 nmol/L), our prevalence of vitamin 252 
D deficiency increases to 81%. The occurrence of low serum 25(OH)D is 35-77% using 253 
a similar cut-point (<30-32 ng/ml) in predominantly non-minority BC survivors,5-7,24 254 
reflecting lower prevalence estimates than our AA BC population. Regardless of these 255 
deficiency definitions, observational data support an inverse relationship between higher 256 
serum 25(OH)D at diagnosis and lower risk for BC progression and mortality.25 257 
Specifically, in an observational cohort of 512 early stage BC survivors, Goodwin et al 258 
showed that low plasma levels of 25(OH)D (<20 ng/ml or <50 nmol/L) at the time of BC 259 
diagnosis were significantly associated with an increased risk of distant recurrence and 260 
death.26 These effects were only modestly attenuated after adjustment for tumor-related 261 
factors. A more recent systematic review and meta-analysis (n=5,691) indicated that low 262 
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blood levels of serum (OH)D were associated with a pooled hazard ratio of 2.1 (95% CI 263 
1.6, 2.8) for recurrence and 1.8 (95% CI 1.4, 2.3) for mortality in women diagnosed and 264 
previously treated for early stage BC.27 Thus, many BC survivors are prescribed 265 
supplemental vitamin D under the clinical presumption that it will positively influence BC 266 
survivorship. It is clear that many of our participants ‘heard this message’ since 60% of 267 
those with evaluable dietary data (n=132) reported ingesting supplemental vitamin D; a 268 
significant predictor of serum 25(OH)D (p<0.001). Based on our deficiency levels, AA 269 
BC survivors may require higher doses to achieve a therapeutic response. Taking into 270 
account our cross-sectional design and the length of time since initial BC diagnosis, we 271 
cannot, however, extrapolate our findings to make assumptions regarding the 272 
survivorship of our participants. Although, vitamin D deficiency has been hypothesized 273 
to contribute to risk of more aggressive BC in AA women,28 the possibility that AA BC 274 
survivors with lower serum 25(OH)D experienced metastasis or mortality closer to the 275 
time of BC diagnosis would have precluded study participation, posing important 276 
confines on these data.  277 
In previous studies, BMI was a significant, inverse predictor of serum 25(OH)D,29-278 
34 perhaps due to vitamin D sequestration into the adipose tissue, alterations in 279 
metabolism from hepatic steatosis or inhibitory effects of adipokines.11 Body 280 
composition is a developing science that examines more than BMI, specifically 281 
accounting for the amount and location of adipose and lean tissue compartments in the 282 
human body.35 Due to recent advances, the precision with which to measure body 283 
composition has substantially increased over the last two decades.36 Despite the known 284 
validity and reliability of DXA in individuals who are lean or obese, 37,38 the current study 285 
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did not find significant associations between serum 25(OH)D and DXA quantified 286 
measures of body composition in our cohort of AA BC survivors with overweight/obesity. 287 
Regardless, this relationship is inconsistent in AA populations,39-41 which is supported 288 
by our study findings. Due to the high prevalence of central obesity in our participants, 289 
we anticipated that VAT would have negatively predicted serum 25(OH)D levels. A 290 
growing body of literature now highlights that AA women may possess higher WC, yet 291 
lower levels of VAT when compared to women of other race/ethnicities.42-46 292 
Interestingly, only WHR, a surrogate marker of android vs. gynoid adiposity, was a 293 
significant determinant of serum 25(OH)D, accounting for 5% of its variability 294 
(p=0.0279). This lack of consistency highlights two concerns. First, WC measures were 295 
taken at the level of the umbilicus. This physical landmark may not always align with the 296 
DXA defined regions of interest for VAT assessment. Second, while DXA provides 297 
estimates of VAT, more importantly, it cannot parse out the deep vs. superficial 298 
subcutaneous adipose tissues. These tissue compartments are only measureable using 299 
computed tomography or magnetic resonance imaging, but are emerging as distinctly 300 
different predictors of metabolic risk.47   301 
Many assays are utilized to quantify 25(OH)D and these can be generally 302 
grouped into 2 categories: immune based and chromatography based.14,48 Due to 303 
superior precision, liquid chromatography tandem mass spectrometry is considered the 304 
’gold standard’ and as such, used a reference measure in comparison studies.14,49-52 305 
Because immunoassays procedures are easily automated, considerably less expensive 306 
and readily available, these methods are most widely used in clinical facilities and 307 
practice. Unfortunately, immunoassays have variable specificity for 25(OH)D2, 308 
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25(OH)D3, the C3-epimer of 25(OH)D and other 25(OH)D metabolites,53 reducing 309 
measurement accuracy as much as 20%.54  Acknowledging this lack of agreement is 310 
important for researchers as it poses serious challenges to explore purported 311 
associations between low serum 25(OH)D, non-skeletal chronic diseases (e.g., cancer)1 312 
and relevant cancer outcomes (i.e., BC recurrence, mortality).27   313 
Several limitations of this investigation merit discussion. First, this study involved 314 
AA BC survivors with overweight/obesity who desired weight loss. While the majority of 315 
AAs in the US population are overweight/obese reflecting good generalizability,55 we did 316 
not have a proportion of AA women with normal BMI or normal adiposity (<32%)56 for 317 
more rigorous comparisons. Second, we did not have measures of parathyroid 318 
hormone; a known determinant of serum 25(OH)D.1 Third, all of our participants were 319 
BC survivors who had received BC treatment; thus, by design, these findings are only 320 
generalizable to other AA BC survivors. Fourth, we were unable to include the dietary 321 
data from our first recruitment site (n=25 women) due to changes in dietary assessment 322 
methodologies. However, based on similarities across recruitment sites, we have no 323 
reason to believe these dietary data would be significantly different than the other 324 
participants. Additionally, this change resulted in missing data related to current 325 
smoking status. Based on data reflective of 90% of the study sample (n=216), no 326 
relationship between serum 25(OH)D and current smoking was detected in univariate 327 
and multivariable modeling. Finally, the likelihood of Type 2 error cannot be ruled out. 328 
However, sensitivity analyses showed no correlation between serum 25(OH)D and 329 
percent body fat (r= -0.07, p=0.28). There were no linear and nonlinear visual patterns 330 
detected between the two measures.   331 
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CONCLUSION  332 
The determination and interpretation of serum 25(OH)D status is complex. It 333 
reflects a clinical scenario plagued by non-harmonious definitions20,21 and employs 334 
methodologies that possess laboratory drift and variation.57 Applying the cut-points of 335 
the Endocrine Society and the IOM, we found that vitamin D deficiency was prevalent in 336 
81% and 43% of our AA BC survivors with overweight/obesity, respectively. While, skin 337 
pigmentation, age and BC stage are not modifiable, vitamin D supplementation, sun 338 
behaviors and WHR are all significant predictors of serum 25(OH)D levels and thus may 339 
serve as potential future points of intervention to improve the vitamin D status of this 340 
minority survivor population.  341 
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Table 1. Baseline clinical characteristics of African-American breast cancer survivor study participants stratified 
by serum 25(OH)D cut-points proposed by the Endocrine Society and the Institute of Medicine (N=244)  
 Endocrine Society21 Institute of Medicine20 
 
 
 
Variablea  
Sufficient 
25(OH) D  
≥ 30 ng/ml 
(≥ 75 nmol/L) 
Insufficient 
25(OH) D 
< 30 ng/ml 
(< 75 nmol/L) 
P valueb Sufficient 
25(OH) D 
≥ 20 ng/ml 
(≥ 50 nmol/L) 
Insufficient 
25(OH) D 
<20 ng/ml 
(< 50 nmol/L) 
P valuec 
N  47  197   138  106   
Age  
[years (SD)] 
61.3 (8.5) 56.5 (10.2) 0.003 58.4 (10.1) 56.1 (9.9) 0.077 
Time since diagnosis 
[years (SD)] 
7.7 (5.7) 6.9 (5.2) 0.376 
 
6.9 (5.9) 7.3 (6.3) 0.475 
Age at diagnosis  
[years (SD)] 
53.4 (10.0) 49.6 (9.9) 0.020 
 
51.5 (10.5) 48.8 (9.0) 0.037 
Self-report breast cancer 
stage (n) 
  0.135   0.001 
Stage I (%) 19  66   47 38   
Stage II (%) 20  78   66  32   
Stage III (%) 3  36   13  26   
Unsure  5  17   12  10   
Co-morbid conditions (n)       
Diabetes 17 39 0.017 34 22 0.475 
High Cholesterol 20 72 0.445 54 38 0.600 
Hypertension 37 107 0.002 90 54 0.025 
Current Smoker (n)d 5 14 0.375 9 10 0.419 
Currently taking vitamin D 
supplements (n)e 
35 97 <0.001 97 35 <0.001 
Education level (n)   0.438   0.823 
High school or less 12 46  36 22  
Some college or 
Associate's degree 
16 77  50 43  
College graduate or 
graduate degree 
19 74  52 41  
Employment (n)   0.004   0.102 
Full-time 21 66  51 36  
Part-time 1 26  16 11  
Retired 19 44  40 23  
Disabled/unable to work 2 32  12 22  
Other 4 29  19 14  
Insurance (n)   0.035   0.403 
None 1 8  6 3  
Public 3 48  26 25  
Medicare 11 48  33 26  
HMO/PPO 32 91  73 50  
Other 0 2  0 2  
Current menopausal status   0.148   0.326 
Pre-menopausal (n) 3 28  15 16  
Post-menopausal (n)  44 169  123 90  
Received chemotherapy 
for breast cancer (n)d 
33  142 0.603 99  76 0.795 
Received radiation therapy 
for breast cancer (n) d 
36  153 0.640 102  87  0.204 
Current endocrine therapy 
for breast cancer (n) d 
13 58 0.716 46 25  0.071 
a Data are presented as mean ± standard deviation (SD) or n. 
b P value reflects comparisons made for > 30 vs. ≤ 30 ng/ml (or > 75 vs. ≤ 75 nmol/L) with bold values signifying statistical 
significance. 
c P value reflects comparisons made for > 20 vs. ≤ 20 ng/ml (or > 50 vs. ≤ 50 nmol/L) with bold values signifying statistical 
significance. 
d Data missing on 25 participants for current smoker and on 5 participants for breast cancer related therapies. 
e Numbers reflect 132 women who reported supplemental vitamin D consumption. 
Table 2. Body composition, dietary intake and sun exposure among African-American breast cancer survivors 
stratified by serum 25(OH)D cut-points proposed by the Endocrine Society and the Institute of Medicine (N=244)  
 Endocrine Society21 Institute of Medicine20 
 
 
 
Variableag 
Sufficient 
25(OH)D  
≥ 30 ng/ml 
(≥ 75 nmol/L) 
Insufficient 
25(OH)D 
< 30 ng/ml 
(< 75 nmol/L) 
 
 
 
P valueb 
Sufficient 
25(OH)D 
≥ 20 ng/ml 
(≥ 50 nmol/L) 
Insufficient 
25(OH)D 
<20 ng/ml 
(< 50 nmol/L) 
 
 
 
P valueb 
N 47 197  138 106  
Body Weight 
(kg) 
95.6 (15.9) 96.2 ( 18.8) 0.859 
 
94.5 (17.1) 98.0 (19.5) 0.141 
Height 
(cm) 
161.9 (5.8) 163.1 (6.5) 0.247 162.6 (6.0) 163.1 (6.8) 0.527 
Body mass indexb 
(kg/m2) 
36.5 (5.9) 36.1 (6.3) 0.674 35.7 (6.0) 36.7 (6.5) 0.221 
Overweight (n) 3 24 0.162 15 12 0.510 
Class 1 Obese (n) 20 79  61 38  
Class 2 Obese (n) 17 63  35 28  
Class 3 Obese (n) 7 55  27 28  
Waist circumference 
(cm) 
112.4 (12.5) 113.7 (15.9) 0.589 
 
112.4 (14.1) 114.8 (16.6) 0.212 
 
Hip circumference 
(cm) 
121.0 (11.3) 120.6 (13.9) 0.870 120.0 (12.9) 121.6 (14.1) 0.367 
Waist to hip ratio 0.93 (0.07) 0.94 (0.09) 0.325 0.93 (0.08) 0.95 (0.09) 0.502 
 
DXA Total fat mass  
(kg) 
44.6 (10.6) 44.7 (13.0) 0.994 
 
43.5 (11.9) 46.2 (13.3) 0.092 
DXA Body fat  
(%) 
46.9 (3.90) 46.2 (5.20) 0.411 
 
45.8 (5.0) 46.9 (4.7) 0.094 
DXA Visceral fat mass 
(kg) 
1.44 (0.67) 1.45 (0.70) 0.925 
 
1.39 (0.67) 1.53 (0.72) 0.120 
 
DXA Android fat mass 
(kg) 
4.01 (1.23) 4.12 (1.50) 0.638 
 
3.93 (1.36) 4.30 (1.51) 0.049 
DXA Gynoid fat mass 
(kg) 
7.56 (2.14) 7.54 (2.54) 0.978 
 
7.33 (2.36) 7.83 (2.57) 0.120 
 
DXA Leg fat mass 
(kg) 
16.57 (4.84) 16.109 (5.75) 0.574 15.83 (5.29) 16.68 (5.93) 0.248 
DXA Total lean mass 
(kg) 
47.22 (5.58) 47.99 (6.90) 0.473 47.56 (6.34) 48.20 (7.06) 0.461 
DXA Appendicular lean 
height (kg/m2) 
8.74 (1.15) 8.82 (1.28) 0.715 8.76 (1.17) 8.87 (1.36) 0.523 
FFQ Energy intake  
(kcals/d)e 
1769 (862) 2091 (1152) 
 
0.094 1769 (813) 2339 (1342) 
 
<0.001 
FFQ Dietary vitamin D 
intake  
(IU/d)e 
102 (80) 116 (100) 0.413 
 
97 (67) 135 (129) 0.01 
FFQ Supplement vitamin 
D intake (IU/d)ef 
352 (194) 317 (158) 0.296 
 
342 (175) 282 (140) 0.073 
 
Daily summer sun 
exposure (hrs) 
2.4 (1.6) 2.5 (1.7) 0.769 
 
2.5 (1.6) 2.5 (1.7) 0.975 
 
Self-reported skin color   <0.001 
 
  0.513 
Fair 3 8   7 4  
Olive 3  7   6 4  
Light brown  20  84   61 43  
Dark brown  14  93   55 52  
Very dark  7 5   9 3  
a Data are presented as mean ± standard deviation (SD) or n. 
b BMI (kg/m2) cut-points defined as: overweight BMI 25.0-29.9; Class 1 obese BMI 30.0-34.9; Class 2 obese BMI 35.0-
39.9; Class 3 obese BMI ≥ 40.0.15 
c P value reflects comparisons made for > 30 vs. ≤ 30 ng/dl (or > 75 vs. ≤ 75 nmol/L) with bold values signifying statistical 
significance. 
d P value reflects comparisons made for > 20 vs. ≤ 20 ng/dl (or > 50 vs. ≤ 50 nmol/L) with bold values signifying statistical 
significance. 
e Due to changes in FFQ version, only dietary data from cohorts 2-8 were evaluable (n=219).  
f These calculations reflect the 132 participants who reported intakes of supplemental vitamin D. 
g Abbreviations used: BMI= Body mass index, FFQ=Food Frequency Questionnaire, DXA=Dual energy x-ray 
absorptiometry 
